BRIEF-Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc.

TNYA

0.00

May 15 (Reuters) - Tenaya Therapeutics Inc TNYA.O:

  • POSITIVE INTERIM DATA FROM COHORTS 1 AND 2 OF TENAYA’S RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 DEMONSTRATED CONSISTENT REDUCTIONS IN ARRHYTHMIA BURDEN FOR ADULTS WITH PKP2-ASSOCIATED ARVC

  • TENAYA THERAPEUTICS INC - ALL PATIENTS ACHIEVE MEAN 64% DECREASE IN DAILY PVC COUNT WITH TN-401

  • TENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG AND 6E13 VG/KG DOSES

  • TENAYA THERAPEUTICS INC - TN-401 ADVERSE EVENTS WERE ASYMPTOMATIC AND SELF-RESOLVED OR RESPONDED TO TREATMENT

Source text: ID:nGNX5fYMBw

Further company coverage: TNYA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.